Extended-release niacin with laropiprant: a review on efficacy, clinical effectiveness and safety

By Yadav Rahul   France Michael   Younis Naveed   Hama Salam   Ammori Basil J   Kwok See   Soran Handrean  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 9, 2012-06 ,pp. : 1345-1362

Informa Healthcare

Access to resources Recommend Favorite

Consistency of Extended-Release Niacin/Laropiprant Effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 Ratio Across Patient Subgroups

By Bays Harold E.  

American Journal of Cardiovascular Drugs, Vol. 12, Iss. 3, 2012-06 ,pp. : 197-206

Adis International

Access to resources Recommend Favorite

Niaspan: managing hyperlipidaemia with extended-release niacin

By Bradley D.  

Pharmaceutical Science & Technology Today, Vol. 3, Iss. 8, 2000-08 ,pp. : 262-263

Elsevier

Access to resources Recommend Favorite

Extended-release niacin for modifying the lipoprotein profile

By Guyton John R  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 6, 2004-06 ,pp. : 1385-1398

Informa Healthcare

Access to resources Recommend Favorite

Niacin Extended-Release/Simvastatin

By Sanford Mark   Curran Monique P.  

Drugs, Vol. 68, Iss. 16, 2008-01 ,pp. : 2373-2386

Adis International

Access to resources Recommend Favorite